Literature DB >> 28284251

Bottom-up or top-down: unit cost estimation of tuberculosis diagnostic tests in India.

S Rupert1, A Vassall2, N Raizada3, S D Khaparde4, C Boehme3, V S Salhotra5, K S Sachdeva4, S A Nair6, A H Van't Hoog7.   

Abstract

SETTING: Of 18 sites that participated in an implementation study of the Xpert® MTB/RIF assay in India, we selected five microscopy centres and two reference laboratories.
OBJECTIVE: To obtain unit costs of diagnostic tests for tuberculosis (TB) and drug-resistant TB.
DESIGN: Laboratories were purposely selected to capture regional variations and different laboratory types. Both bottom-up and the top-down methods were used to estimate unit costs.
RESULTS: At the microscopy centres, mean bottom-up unit costs were respectively US$0.83 (range US$0.60-US$1.10) and US$12.29 (US$11.61-US$12.89) for sputum smear microscopy and Xpert. At the reference laboratories, mean unit costs were US$1.69 for the decontamination procedure, US$9.83 for a solid culture, US$11.06 for a liquid culture, US$29.88 for a drug susceptibility test, and US$18.18 for a line-probe assay. Top-down mean unit cost estimates were higher for all tests, and for sputum smear microscopy and Xpert these increased to respectively US$1.51 and US$13.58. The difference between bottom-up and top-down estimates was greatest for tests performed at the reference laboratories.
CONCLUSION: These unit costs for TB diagnostics can be used to estimate resource requirements and cost-effectiveness in India, taking into account geographical location, laboratory type and capacity utilisation.

Entities:  

Mesh:

Year:  2017        PMID: 28284251     DOI: 10.5588/ijtld.16.0496

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  12 in total

1.  Estimating TB diagnostic costs incurred under the National Tuberculosis Elimination Programme: a costing study from Tamil Nadu, South India.

Authors:  Malaisamy Muniyandi; Jayabal Lavanya; Nagarajan Karikalan; Balakrishnan Saravanan; Sellappan Senthil; Sriram Selvaraju; Rajesh Mondal
Journal:  Int Health       Date:  2021-12-01       Impact factor: 2.473

2.  Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India's public sector.

Authors:  David J Lee; Nagalingeswaran Kumarasamy; Stephen C Resch; Gomathi N Sivaramakrishnan; Kenneth H Mayer; Srikanth Tripathy; A David Paltiel; Kenneth A Freedberg; Krishna P Reddy
Journal:  PLoS One       Date:  2019-07-02       Impact factor: 3.240

3.  Cost and operational impact of promoting upfront GeneXpert MTB/RIF test referrals for presumptive pediatric tuberculosis patients in India.

Authors:  Sanjay Sarin; Sophie Huddart; Neeraj Raizada; Debadutta Parija; Aakshi Kalra; Raghuram Rao; Virender Singh Salhotra; Sunil D Khaparde; Catharina Boehme; Claudia M Denkinger; Hojoon Sohn
Journal:  PLoS One       Date:  2019-04-01       Impact factor: 3.240

4.  Development and evaluation of novel bio-safe filter paper-based kits for sputum microscopy and transport to directly detect Mycobacterium tuberculosis and associated drug resistance.

Authors:  Divya Anthwal; Surabhi Lavania; Rakesh Kumar Gupta; Ajoy Verma; Vithal Prasad Myneedu; Prem Prakash Sharma; Hitesh Verma; Viveksheel Malhotra; Ashawant Gupta; Nalini Kant Gupta; Rohit Sarin; Sagarika Haldar; Jaya Sivaswami Tyagi
Journal:  PLoS One       Date:  2019-08-13       Impact factor: 3.240

5.  Standardized framework for evaluating costs of active case-finding programs: An analysis of two programs in Cambodia and Tajikistan.

Authors:  Youngji Jo; Farangiz Mirzoeva; Monyrath Chry; Zhi Zhen Qin; Andrew Codlin; Oktam Bobokhojaev; Jacob Creswell; Hojoon Sohn
Journal:  PLoS One       Date:  2020-01-27       Impact factor: 3.240

6.  The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China.

Authors:  Gabriela B Gomez; Richard G White; Chathika K Weerasuriya; Rebecca C Harris; C Finn McQuaid; Fiammetta Bozzani; Yunzhou Ruan; Renzhong Li; Tao Li; Kirankumar Rade; Raghuram Rao; Ann M Ginsberg
Journal:  BMC Med       Date:  2021-02-26       Impact factor: 8.775

7.  Scaling-up the Xpert MTB/RIF assay for the detection of tuberculosis and rifampicin resistance in India: An economic analysis.

Authors:  Sunil Khaparde; Neeraj Raizada; Sreenivas Achuthan Nair; Claudia Denkinger; Kuldeep Singh Sachdeva; Chinnambedu Nainarappan Paramasivan; Virender Singh Salhotra; Anna Vassall; Anja Van't Hoog
Journal:  PLoS One       Date:  2017-09-07       Impact factor: 3.240

8.  Predictors of recurrent TB in sputum smear and culture positive adults: a prospective cohort study.

Authors:  Grace Muzanyi; Y Mulumba; Paul Mubiri; Harriet Mayanja; John L Johnson; Ezekiel Mupere
Journal:  Afr Health Sci       Date:  2019-06       Impact factor: 0.927

9.  The potential deployment of a pan-tuberculosis drug regimen in India: A modelling analysis.

Authors:  Nimalan Arinaminpathy; Gabriela B Gomez; Kuldeep S Sachdeva; Raghuram Rao; Malik Parmar; Sreenivas A Nair; Kiran Rade; Sameer Kumta; David Hermann; Christy Hanson; Daniel P Chin; Puneet Dewan
Journal:  PLoS One       Date:  2020-03-27       Impact factor: 3.240

10.  Genotype®MTBDRplus and Xpert®MTB/RIF in the diagnosis of tuberculosis and resistant tuberculosis: cost analysis in a tertiary referral hospital.

Authors:  Valéria Martins Soares; Isabela Neves de Almeida; Maria Cláudia Vater; Suely Alves; Lida Jouca de Assis Figueredo; Luciene Scherer; Afrânio Lineu Kritski; Wânia da Silva Carvalho; Silvana Spindola de Miranda
Journal:  Rev Soc Bras Med Trop       Date:  2020-02-07       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.